Literature DB >> 23979967

Limitation of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography (FDG-PET) to detect early synchronous primary cancers in patients with untreated head and neck squamous cell cancer.

Atsushi Hanamoto1, Yukinori Takenaka, Eku Shimosegawa, Yoshifumi Ymamamoto, Tadashi Yoshii, Susumu Nakahara, Jun Hatazawa, Hidenori Inohara.   

Abstract

OBJECTIVE: Patients with head and neck squamous cell carcinoma (HNSCC) often develop synchronous multiple primary cancers. It is important to detect second primary cancer in HNSCC patients, because it influences treatment selection of primary cancer. The aim of this study was to evaluate the utility of 2-deoxy-2-[F-18]fluoro-D-glucose (FDG)-positron emission tomography (PET) for detecting synchronous primary cancers at the initial staging of patients with HNSCC.
METHODS: Three hundred and forty-seven patients with untreated HNSCC underwent FDG-PET with or without computed tomography fusion and other routine workups, including upper gastrointestinal Lugol chromoendoscopy, for the initial staging. We examined the prevalence of second primary cancer in these patients and the utility of PET.
RESULTS: We identified 57 synchronous primary cancers in 53 patients, of which only 33 % were detected with PET. The most common site for the second primary cancer was the esophagus (49 %), followed by stomach (14 %) and head and neck (11 %). Most early-stage esophageal cancers and stomach cancers were detected using Lugol chromoendoscopy but not PET.
CONCLUSION: Although PET is useful for detecting synchronous primary cancers, it is not a sensitive technique for detecting early esophageal cancers and gastric cancers. Therefore, Lugol chromoendoscopy is indispensable for detecting synchronous upper gastrointestinal cancers in HNSCC patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23979967     DOI: 10.1007/s12149-013-0765-x

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  5 in total

1.  Guidelines for the Surgical Management of Laryngeal Cancer: Korean Society of Thyroid-Head and Neck Surgery.

Authors:  Soon-Hyun Ahn; Hyun Jun Hong; Soon Young Kwon; Kee Hwan Kwon; Jong-Lyel Roh; Junsun Ryu; Jun Hee Park; Seung-Kuk Baek; Guk Haeng Lee; Sei Young Lee; Jin Choon Lee; Man Ki Chung; Young Hoon Joo; Yong Bae Ji; Jeong Hun Hah; Minsu Kwon; Young Min Park; Chang Myeon Song; Sung-Chan Shin; Chang Hwan Ryu; Doh Young Lee; Young Chan Lee; Jae Won Chang; Ha Min Jeong; Jae-Keun Cho; Wonjae Cha; Byung Joon Chun; Ik Joon Choi; Hyo Geun Choi; Kang Dae Lee
Journal:  Clin Exp Otorhinolaryngol       Date:  2017-01-03       Impact factor: 3.372

2.  Clinical and Prognostic Analysis of Hypopharyngeal Squamous Cell Carcinoma with Synchronous and Metachronous Multiple Malignancies.

Authors:  Keisuke Yamamoto; Kenichi Takano; Atsushi Kondo; Makoto Kurose; Kazufumi Obata; Tetsuo Himi
Journal:  In Vivo       Date:  2018 Jan-Feb       Impact factor: 2.155

3.  Clinical outcomes of synchronous head and neck and esophageal cancer.

Authors:  Jae Won Park; Sang-Wook Lee
Journal:  Radiat Oncol J       Date:  2015-09-30

4.  Development and validation of a new comorbidity index for patients with head and neck squamous cell carcinoma in Japan.

Authors:  Yukinori Takenaka; Norihiko Takemoto; Ryohei Oya; Naoki Ashida; Takahiro Kitamura; Kotaro Shimizu; Kazuya Takemura; Takahiro Michiba; Atsushi Hanamoto; Motoyuki Suzuki; Yoshifumi Yamamoto; Atsuhiko Uno; Hidenori Inohara
Journal:  Sci Rep       Date:  2017-08-04       Impact factor: 4.379

5.  A Review of Controversial Issues in the Management of Head and Neck Cancer: A Swiss Multidisciplinary and Multi-Institutional Patterns of Care Study-Part 1 (Head and Neck Surgery).

Authors:  Pavel Dulguerov; Martina A Broglie; Guido Henke; Marco Siano; Paul Martin Putora; Christian Simon; Daniel Zwahlen; Gerhard F Huber; Giorgio Ballerini; Lorenza Beffa; Roland Giger; Sacha Rothschild; Sandro V Negri; Olgun Elicin
Journal:  Front Oncol       Date:  2019-10-24       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.